Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with stage III, stage IV, or returned (relapsed) cervical cancer, confirmed through tissue testing (biopsy).
- People aged 18 to 70 years old.
- People who have waited at least 4 weeks since their last chemotherapy or radiation treatment, and at least 2 weeks since last taking steroid or immune-suppressing medications.
- People whose side effects from chemotherapy have resolved.
- People whose cancer tissue tests show high levels (above 2+) of certain markers, such as GD2, PSMA, Muc1, or Mesothelin, detected through laboratory testing of the tumour sample.
- People who are largely able to carry out daily activities, with only minor limitations (this is measured using a standard medical scale called ECOG, with a score of 0 or 1).
- People whose doctors estimate they are expected to live at least 12 weeks.
- People whose blood counts meet minimum levels — specifically, a certain level of infection-fighting white blood cells (neutrophils) and platelets (cells that help blood clot).
- People whose kidney and liver are functioning within acceptable ranges, based on specific blood test results.
- People whose blood oxygen level is 90% or above.
- People who are willing and able to provide written consent before any study procedures begin.
Who may not be able to join:
- People whose tumour is blocking their airway.
- People with a history of epilepsy or other conditions affecting the brain or nervous system.
- People who need to take corticosteroid (steroid) tablets or other immune-suppressing medications on an ongoing basis.
- People with a history of a serious heart rhythm condition affecting the QT interval (a measurement of the heart's electrical activity) (confirm with trial site).
- People with a history of serious harmful reactions to a medication called cyclophosphamide.
- People who have taken part in another clinical trial, or used another experimental drug, within the 28 days before the study start date.
- People whose kidney or liver blood test results fall outside the acceptable ranges specified by the trial.
- People who are pregnant or currently breastfeeding.
- People who have a serious active infection at the time of screening.
- People with active HIV, Hepatitis B, or Hepatitis C infection, or any infection that is not under control.
- People whom the trial investigators consider unlikely to be suitable or able to follow the study requirements for any reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of CART cells in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.